We've known that Intercept Pharmaceuticals Inc.'s FLINT trial evaluating obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) was positive since the data safety monitoring stopped the trial early for positive efficacy in January. (See BioWorld Today, Jan. 10, 2014.) Read More
Researchers at Medimmune Inc. have reported that a bispecific antibody, MEDI3902, could protect mice from infection with Pseudomonas aeruginosa, a bacterium that causes hospital-acquired pneumonia and is responsible for about 10 percent of all hospital-acquired infections in the U.S. Read More
